Prostate Cancer International is
for 2011 by Great NonProfits
The evidence supporting a role for the combination of dutasteride with ketoconazole as a form of second- or third-line hormone therapy for patients with castration-resistant prostate cancer (CRPC) appears to be increasing.
Filed under: Management, Treatment, Uncategorized | Tagged: castration-resistant prostate cancer, CRPC, dutasteride, ketoconazole | 1 Comment »
In today’s news reports from sources other than the ASTRO meeting, we note items dealing with: PSA bounce in brachytherapy patients Fatal prostate cancer and a history of smoking Ketoconazole + dutasteride in treatment of CRPC
Filed under: Management, Prevention, Risk, Treatment | Tagged: Avodart, brachytherapy, castration-resistant prostate cancer, CRPC, dutasteride, ketoconazole, PSA bounce, smoking | 1 Comment »
Satraplatin is an oral platinum analog that was tested (in combination with prednisone) in a multinational, double-blind, randomized, placebo-controlled, Phase III clinical trial in patients with metastatic castrate-refractory prostate cancer (CRPC) who had progressed after one prior chemotherapy regimen.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, satraplatin | Leave a Comment »
According to a media release from Medivation, Inc. earlier today, the company has treated the first patient in a Phase III clinical trial of the novel androgen receptor antagonist MDV3100 in advanced prostate cancer.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, MDV3100 | 2 Comments »
Today’s news reports cover items on: Extent and number of biopsy cores and eligibility for active surveillance Intermittent vs. complete androgen deprivation Hormone therapy and risk for cardiovascular disease and death Surrogate markets for disease progression in men with CRPC
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, androgen deprivation, biopsy, cardiovasular, castration-resistant prostate cancer, complete, CRPC, hormone therapy, intermittent, marker, protocol, side effects, surrogate | Leave a Comment »
According to a media release issued earlier today, Takeda Pharmaceuticals and it’s wholly owned subsidiary, Millennium, are starting the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, TAK-700 | Leave a Comment »
Today’s news reports address: Smoking and risk for prostate cancer Assessing risk for a positive second biopsy after a prior negative biopsy Smoking pot won’t cure your cancer but … Pemetrexed not effective as a single agent in CRPC patients after docetaxel failure
Filed under: Diagnosis, Drugs in development, Management, Prevention, Risk, Treatment, Uncategorized | Tagged: biopsy, canabis, castration-resistant prostate cancer, CPRC, pemetrexed, pot, risk, smoking | Leave a Comment »
According a media release earlier today, Bellicum Pharmaceuticals, Inc. has announced dosing of their first patient in a Phase I/II clinical trial of “BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer.”
Filed under: Drugs in development, Management, Treatment | Tagged: BP-GMAX-CD1, castration-resistant prostate cancer, CRPC, vaccine | 3 Comments »
For readers who are interested in OncoGenex Pharmaceuticals‘ plans for the future development of Phase III trial of OGX-011 (an antisense compound that acts as a clusterin growth inhibitor), it’s worth reading Luke Timmerman’s article on Xconomy.com, which is based on a recent interview with OncoGenex’s CEO, Scott Cormack.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant prostate cancer, CRPC, OGX-011 | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site